CENTRAL MANCHESTER UNIVERSITY HOSPITALS NHS FOUNDATION TRUST

Transcription

1 CENTRAL MANCHESTER UNIVERSITY HOSPITALS NHS FOUNDATION TRUST Agenda Item 9.3 Report of: Paper prepared by: Robert Pearson Medical Director, CMFT Lisa Miles Senior Project Manager, Research & Innovation Date of paper: 14 th April 2016 Subject: Update on BRC/CRF applications Research and infrastructure currently hosted by CMFT Purpose of Report: Indicate which by Information to note Support Resolution Approval Consideration of Risk against Key Priorities is in the process of applying to the National Institute for Health Research (NIHR) to be designated as a Biomedical Research Centre (BRC) and to re-fund the Clinical Research Facility (CRF). CMFT has been asked to lead on both bids for which will be a key step in consolidating our research infrastructure across the City. The NIHR BRC funding scheme aims to provide funding for NHS/University partnerships in England that have a very substantial portfolio of world-class biomedical research across either a range of clinical or research areas, or in a specific clinical or research area. In all cases NIHR BRCs will contain substantial existing critical mass, a significant number of researcher leaders, and a wide range of underpinning facilities. CRFs are dedicated and purpose built facilities with specialist clinical research and support staff from universities and NHS Trusts work together on patient-orientated commercial and noncommercial experimental medicine studies. The BRC funding call is a new, open call. An unsuccessful bid would limit the Trust s ability to grow as an internationally renowned research centre and would impact on its ability to leverage in research funding in the future.

2 In addition, failure to secure a BRC would be damaging to as, together with University, the Trust combines expertise with that of five other local NHS organisations through MAHSC. MAHSC is one of only six AHSCs in England set up to interconnect existing research activity and it is expected that every AHSC has a BRC embedded within the structure. The CRF submission is a renew and refresh bid and therefore there is no concern around a loss of funding to support this existing infrastructure. Linking in with the Trust vision to position CMFT as an internationally renowned centre for research and innovation, it is important that both the CRF and BRC are funded. Recommendations The Board is asked to note the status of the NIHR infrastructure bids for which CMFT is lead applicant partnering with UoM. The Board is asked to note the infrastructure currently hosted by CMFT.

3 Introduction The Board approved a One approach to the development of infrastructure in Research and Innovation at its meeting in January This paper provides an update on progress in the One approach to current funding rounds, and notes the growing externally funded and supported infrastructure based on the central campus. Current NIHR infrastructure bids led by the Trust NIHR Biomedical Research Centre The BRC - Pre qualifying questionnaire submitted to the NIHR on 12 th February for a BRC: Ian Bruce appointed as BRC Director. CMFT will host the BRC (in partnership with UoM) and subcontract to associated Trusts Proposed themes: Research Theme Theme Lead and Trust Total Indicative Costs Musculoskeletal Anne Barton 5.5m CMFT Hearing Health Kevin Munro CMFT Respiratory Medicine Jorgen Vestbo UHSM Dermatology Chris Griffiths 3.5m SRFT Cancer Prevention & Early Detection Gareth Evans 3.0m CMFT/Christie Advanced Radiotherapy Catharine West Christie Precision Treatment of Cancer Caroline Dive Christie TOTAL 30m - NIHR has confirmed all themes are approved for full submission - 22 nd April Deadine for receipt of full applications 3 rd June International Selection Panel interviews July DH confirms selected NIHR BRCs August/September Funding over 5 years from 1 st April 2017 to 31 st March NIHR Clinical Research Facility The One CRF At present, Clinical Research Facilities in (at CMFT, Christie and UHSM) are funded separately. Following a competition and review by panel, MAHSC appointed CMFT to lead the renew and refresh bid for the One CRF, encompassing the three CRFs into a single bid. Professor Nick Webb (CMFT) appointed as lead CRF Director and Helen Pidd (CMFT) appointed as lead CRF Manager. Single stage application process with deadline for application - 22nd June Decision expected July/August Funding over 5 years from 1 st April 2017 to 31 st March 2022.

4 Existing R&I Infrastructure hosted by the Trust Infrastructure Musculoskeletal Biomedical Research Unit (BRU) Clinical Research Facility (Adult and Paediatric) Centre for Advanced Discovery and Experimental Therapeutics (CADET) NIHR Local Clinical Research Network (LCRN): Greater Molecular Pathology Innovation Centre (MMPathIC) Partner organisations, funding and location CMFT & UoM. 4.95m NIHR funding over 5 years ( ). Stopford (UoM), Kellgren (CMFT), CRF, Nowgen Centre. CMFT & UoM. 5.5m NIHR funding over 5 years ( ). Adult CRF Grafton Street (adjacent to MRI main entrance). Children s CRF (CCRF) 1st Floor Ward 79, RMCH Institute of Human Development in FMHS (UoM). Initial funding of ~ 3m obtained from the NIHR BRC, DH and NWDA. Located within the Trust site (adjacent to the Biobank). Funded by the NIHR - 18M Contract hosted by CMFT for 15 NHS Trusts. Located in ICON buiding on 1st floor Initial 4 year period ( ) - 2.9m from the Medical Research Council and the Engineering and Physical Sciences Research Council, further 1.9m committed by UoM, industry and NHS partners. Remit An infrastructure and platform for delivering experimental medicine research to assess and improve response in the prevention and treatment of musculoskeletal disorders. Seven research themes. In : - 47 projects supported - 45 publications - 5,211 patients recruited into BRU studies m external grant income leveraged Dedicated and purpose built clinical research facility supports world-class experimental medicine research, to give more patients the opportunity to take part in research studies and to expand and strengthen the research portfolio. Research strategy focuses on four key areas inflammation and repair, mental health and neurodegenerative disorders, women s and children s health and heart disease and diabetes. CADET uses metabolomics and proteomics to identify and develop new and improved therapeutics, with main disease targets of: diabetes mellitus and its complications; chronic cardiovascular diseases; adult-onset dementia, particularly Alzheimer s disease; age-related macular degeneration (AMD). The LCRN helps to increase the opportunities for patients to take part in clinical research providing funding for service support costs to 15 NHS organisations; ensures studies are carried out efficiently; and facilitates commercial contract clinical research in the NHS within the Greater region. A total of six nodes funded bringing researchers, clinicians and industry together to develop molecular diagnostic tools, to enable stratification, in disease areas such as cancer, respiratory diseases, digestive disease, infections, rheumatoid arthritis, psoriasis and lupus.

5 Experimental Cancer Medicine Centre (ECMC) Network CMFT Biobank Based in CityLabs (CMFT). Led by UoM. ECMC is funded by the NIHR at CMFT with an award of 1.2M over 5 years We are starting the rebidding process this year. Initially funded by the NWDA until Now funded through cost recovery model within the R&I Division Agenda Item 9.3 By the end of the four years, researchers will have tested six biomarkers for their potential to indicate disease and will be working to roll these out across the NHS. The paediatric Experimental Cancer Medicine Centre (ECMC) Network is a collaboration of world-leading scientists and clinicians who bring together expertise and techniques to drive the discovery,development and testing of new anti-cancer treatments and biomarkers in early phase studies and trials. The CMFT Biobank sources, stores, prepares and analyses human biological samples to support clinical trials and research projects led by the NHS, universities and commercial partners. All samples collected have full ethical approval and are handled in accordance with the requirements of the Human Tissue Act 2004 and under the governance of the Human Tissue Authority (HTA) Licence (#12552). Recommendations: The Board is asked to note the status of the NIHR infrastructure bids for which CMFT is lead applicant partnering with UoM. The Board is asked to note the infrastructure currently hosted by CMFT.